Vanda gets FDA nod for atypical antipsychotic Bysanti
Vanda gets FDA nod for atypical antipsychotic Bysanti
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.
Vanda gets FDA nod for atypical antipsychotic Bysanti
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.